By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vicuron Pharmaceuticals, Inc. (Formerly Versicor) 

34790 Ardentech Court

Fremont  California  94555  U.S.A.
Phone: 510-739-3000 Fax: 510-739-3003




Novartis Pharmaceuticals Corporation  Deformylase and MUR: Pathway inhibitors for novel mechanism based antimicrobial drugs

Pharmacia & Upjohn (Merged to form Pharmacia Corp)  Second generation antimicrobials for both community based and hospital markets

Company News
Oscient Pharmaceuticals Corporation (OSCI) Acquires Expanded Worldwide Rights To Lead Clinical Candidate Ramoplanin 2/8/2006 10:41:13 AM
East Bay Biotechs Hit Sales Block 1/3/2006 11:44:06 AM
Vicuron Pharmaceuticals, Inc. (MICU) Extends Pfizer Inc. (PFE) Deal To Develop Oral Antibiotics For Community Market10/19/2005 5:13:10 PM
Vicuron Pharmaceuticals, Inc. (MICU) Announces Fourth Quarter 2004 Financial Results10/19/2005 5:12:59 PM
Vicuron Pharmaceuticals, Inc. (MICU) To Present At The SG Cowen & Co., LLC 25th Annual Health Care Conference10/19/2005 5:12:59 PM
Vicuron Pharmaceuticals, Inc. (MICU) Provides Update On Novartis Pharma AG (NVS) Peptide Deformylase Inhibitor Program; Suspension Of Phase I First Lead Candidate In Favor Of Second Compound10/19/2005 5:12:55 PM
Vicuron Pharmaceuticals, Inc. (MICU) To Present At The Wells Fargo Securities Healthcare Conference10/19/2005 5:12:51 PM
Vicuron Pharmaceuticals, Inc. (MICU) Granted Priority Review Of Dalbavancin NDA By FDA In Complicated Skin And Soft Tissue Infections10/19/2005 5:12:49 PM
Vicuron Pharmaceuticals, Inc. (MICU) To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 200510/19/2005 5:12:45 PM
The Day In Review: Biotech Consolidates After Recent Gains10/19/2005 5:12:38 PM